Elevance Health, Inc. $ELV Position Trimmed by Bokf Na

09 May 2026, 04:19 by Renee Jackson · The Cerbat Gem

Bokf Na trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 61.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,941 shares of the company’s stock after selling 4,704 shares during the quarter. Bokf Na’s holdings in Elevance Health were worth $1,031,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Murphy Middleton Hinkle & Parker Inc. acquired a new position in Elevance Health in the fourth quarter valued at about $5,941,000. Evergreen Wealth Management LLC boosted its position in Elevance Health by 33.5% in the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock valued at $5,584,000 after buying an additional 4,336 shares in the last quarter. Blume Capital Management Inc. boosted its position in Elevance Health by 236.7% in the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after buying an additional 4,320 shares in the last quarter. Victory Capital Management Inc. boosted its position in Elevance Health by 31.1% in the third quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock valued at $149,182,000 after buying an additional 109,462 shares in the last quarter. Finally, Caprock Group LLC acquired a new position in Elevance Health in the third quarter valued at about $1,638,000. 89.24% of the stock is currently owned by institutional investors.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

Positive Sentiment: Elevance beat first-quarter expectations and raised EPS guidance, which is helping support investor confidence in the company’s near-term outlook. A Look At Elevance Health (ELV) Valuation After Q1 Beat And Raised EPS Guidance
Positive Sentiment: Zacks Research lifted FY2026 EPS estimates to $26.79 from $25.53, matching the consensus estimate and signaling stronger expected earnings this year.
Positive Sentiment: Zacks also raised FY2027 EPS estimates to $28.51 from $28.40, and increased its Q2 2027 forecast to $7.23 from $7.20, suggesting analysts still see healthy longer-term profitability.

Elevance Health Price Performance

ELV opened at $377.66 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24. The company has a fifty day simple moving average of $312.92 and a 200 day simple moving average of $332.13. The stock has a market cap of $82.01 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.12 and a beta of 0.66.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the prior year, the company earned $11.97 EPS. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.

Analyst Ratings Changes

ELV has been the topic of a number of recent analyst reports. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and boosted their price target for the company from $405.00 to $435.00 in a research report on Wednesday, April 29th. JPMorgan Chase & Co. boosted their price target on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Sanford C. Bernstein boosted their price target on shares of Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a research report on Friday, April 24th. Finally, Wells Fargo & Company reduced their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $384.58.

Read Our Latest Analysis on ELV

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.